TAM (Treatments and Medicines) NHS Highland
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Injection (Prostap DCS®) 3·75mg, 11·25mg (specialist use only)
Dosage:
By subcutaneous injection, 3·75mg every month, 11·25mg every 3 months.
Prostate cancer: gonadorelin analogues, and gonadotrophin-releasing hormone antagonists (Formulary: Malignant disease)
What's new / Latest updates
15/01/26 (v1.1)
- relugolix tablets 120mg removed as not used.
The gonadorelin analogues have similar efficacy in reducing testosterone levels and similar side-effect profiles. Leuprorelin (Prostap DCS®) is recommended as first-choice in NHS Scotland.
For the use of gonadorelin analogues in
Important: Therapy notes
Each vial includes an overage to allow administration of the dose.
Important: Formulation and dosage details
Formulation:
Injection 11·25mg, 22·5mg (specialist use only)
Dosage:
By intramuscular injection, 11·25mg every 3 months or 22·5mg every 6 months.
Important: Therapy notes
The gonadotrophin-releasing hormone antagonist degarelix will be initiated by specialists in selected patients with advanced, hormone-naïve prostate cancer. See degarelix shared care protocol.
Important: Formulation and dosage details
Formulation:
Injection 80mg, 120mg